873924-08-4

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 9-OXO-3-AZASPIRO[5.5]UNDECANE-3-CARBOXYLATE is used as a chemical intermediate for the preparation of benzothiazole derivatives. These derivatives are employed as IRAK degraders for their potential role in modulating inflammatory responses and treating inflammatory diseases.

Upstream product

• 873924-07-3 9-oxo-3-azaspiro[5.5]undec-7-ene-3-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1225437-09-1 3-azaspiro[5.5]undecan-9-one hydrochloride 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 160133-32-4 ethyl 2-[1-benzyl-4-(2-ethoxy-2-oxoethyl)-4-piperidyl]acetate 
• 6457-49-4 4-piperidinemethanol 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 1225437-05-7 3,3'-(piperidine-4,4-diyl)dipropanoic acid hydrochloride 
• 1225437-06-8 dimethyl 3,3'-(piperidine-4,4-diyl)dipropanoate hydrochloride 
• 170228-79-2 tert-butyl 4,4-bis(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate 
• 1225437-07-9 Dimethyl 3,3'-(1-(tert-butoxycarbonyl)piperidine-4,4-diyl)dipropanoate 
• 1225437-08-0 3-tert-butyl 8-methyl 9-oxo-3-azaspiro[5.5]undecane-3,8-dicarboxylate 
• 1225437-04-6 tert-butyl 4,4-bis(2-cyanoethyl)piperidine-1-carboxylate 
• 160133-33-5 1-benzylpiperidine-4,4-diethanol 

Downstream Products

• 918644-73-2 tert-butyl 9-hydroxy-3-azaspiro[5.5 ]undecane-3-carboxylate 
• 918644-75-4 9-(3,4-dichloro-phenylamino)-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester 
• 918651-00-0 9-(3,4-dichloro-phenyl)-9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester 
• 1225437-13-7 tert-Butyl 9-(3-fluorophenyl)-9-(pyrrolidin-1-yl)-3-azaspiro[5.5]undecane-3-carboxylate 
• 1246507-88-9 tert-butyl 9-(4-tert-butylpiperazin-1-yl)-3-azaspiro[5.5]undecane-3-carboxylate 
• 1272758-41-4 9-amino-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester 
• 1599478-66-6 C₂₀H₂₅ClF₃NO₃ 
• 1416173-70-0 tert-butyl 9-{2-[4-(methanesulfonyl)phenoxy]ethyl}-3-azaspiro[5.5]undecane-3-carboxylate 
• 1416173-83-5 tert-butyl 9-{3-[4-(methanesulfonyl)phenoxy]propyl}-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-12-6 9-(3,3-Difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane 
• 1225437-01-3 tert-Butyl 9-(azetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-11-5 tert-Butyl 9-(3,3-difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225436-55-4 1-(9-(azetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)ethanone 
• 1225436-57-6 1-[3-(3-fluorophenyl)-3-pyrrolidin-1-yl-9-azaspiro[5.5]undecan-9-yl]-2-[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-piperidin-2-yl]-ethanone 

Relevant academic research and scientific papers

PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted heteroaryl compound and a composition thereof, and applications of the compound and the composition. The compound is a compound as shown in a formula I, or stereoisomer, tautomer, oxynitride, solvate, metabolite, pharmaceutically-acceptable salt or prodrug of the compound as shown in the formula I. The invention also provides a pharmaceutical composition containing the above-mentioned compound; and the above-mentioned compound and the pharmaceutical composition are capable of adjusting the activity of JAK kinases and are applied in prevention, treatment, therapy and alleviation of JAK kinase mediated diseases or disorders.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted ceteroary compound as well as a composition and a purpose thereof. The substituted ceteroary compound is a compound shown as a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the pharmaceutically acceptable salt of the compound shown as the formula (I) and is used for regulating diseases or disorders mediated by one kind or various kinds of Janus kinase activities. The invention also provides a medicine composition containing the compound and a method of treating or alleviating the disease or disorder degree of a patient by inhibiting the Janus kinase activity.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and composition thereof, and applicaitons of compounds and composition

The invention provides substituted heteroaryl compounds and a composition thereof, and applicaitons of the compounds and the composition. The compounds are compounds represented by the formula (I) or the formula (II) or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the compounds represented by the formula (I) or the formula (II). The invention also provides the pharmaceutical composition comprising the compounds; the compounds and the pharmaceutical composition can adjust the activity of protein kinase, and are used for prevention, processing, treatment and remission of diseases or disorders mediated by the protein kinase.

Spiro aryl phosphorus oxide or sulfide

The invention discloses a spiro aryl phosphorus oxide or sulfide as ALK inhibitor, and in particular discloses a compound shown in a formula (I) as an ALK inhibitor or a pharmaceutically acceptable salt thereof.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis